Literature DB >> 21120776

Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms.

Y Sawai1, K Yamao, V Bhatia, T Chiba, N Mizuno, A Sawaki, K Takahashi, M Tajika, Y Shimizu, Y Yatabe, A Yanagisawa.   

Abstract

BACKGROUND AND STUDY AIMS: Side-branch intraductal papillary mucinous neoplasms (SB-IPMNs), and associated synchronous and metachronous pancreatic cancers are increasingly detected as imaging modalities become more sensitive. We investigated the natural history of SB-IPMN, and the incidence and characteristics of pancreatic cancers among patients undergoing long-term follow-up. PATIENTS AND METHODS: We reviewed the clinical, imaging, and pathological features in 103 patients, diagnosed at the Aichi Cancer Center between September 1988 and September 2006 as having SB-IPMN, and conservatively followed up for ≥ 2 years (median 59 months) based on an endoscopic ultrasonography (EUS) database.
RESULTS: 74 (71.8 %) patients had nonprogressive lesions. Overall, six patients (5.8 %) developed pancreatic cancers during follow-up, with intraductal papillary mucinous (IPM) carcinoma in four, and ductal carcinoma of pancreas that was not IPMN in two patients. Of the six pancreatic cancers, five were diagnosed at a resectable stage. The 5-year and 10-year actuarial rates of development of pancreatic cancer were 2.4 % and 20.0 %, respectively. Although, at the last follow-up, cyst size, main pancreatic duct (MPD) diameter, mural nodule size, and frequency of metachronous and/or synchronous cancers of other organs were significantly higher in patients who developed IPM carcinoma, resected SB-IPMNs without mural nodules and dilated MPDs had no IPM carcinomas.
CONCLUSIONS: The frequency of pancreatic cancers is high on long-term follow-up of SB-IPMN. Although conservative management is appropriate for selected patients, regular and long-term imaging, especially by EUS is essential, even if SB-IPMN remains unchanged for 2 years. Presence of mural nodule and dilated MPD seem to be more appropriate indicators for resection than cyst size alone for SB-IPMNs. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2010        PMID: 21120776     DOI: 10.1055/s-0030-1255971

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  28 in total

Review 1.  IPMN: surgical treatment.

Authors:  Reto M Käppeli; Sascha A Müller; Bianka Hummel; Christina Kruse; Philip Müller; Jürgen Fornaro; Alexander Wilhelm; Marcel Zadnikar; Bruno M Schmied; Ignazio Tarantino
Journal:  Langenbecks Arch Surg       Date:  2013-09-03       Impact factor: 3.445

Review 2.  [Intraductal papillary mucinous neoplasia: which findings support observation?].

Authors:  J Mayerle; M Kraft; P Menges; P Simon; J Ringel; L I Partecke; C D Heidecke; M M Lerch
Journal:  Chirurg       Date:  2012-02       Impact factor: 0.955

Review 3.  [Surgical therapy of intraductal papillary mucinous neoplasms of the pancreas].

Authors:  S Fritz; M W Büchler; J Werner
Journal:  Chirurg       Date:  2012-02       Impact factor: 0.955

Review 4.  Intraductal papillary mucinous neoplasms of the pancreas--a surgical disease.

Authors:  Jens Werner; Stefan Fritz; Markus W Büchler
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-03-06       Impact factor: 46.802

5.  Metachronous double cancer after curative resection for pancreatic adenocarcinoma: report of four cases.

Authors:  Yoshito Ikematsu; Hiroaki Tamura; Tadataka Hayashi; Yuji Tokunaga; Yuki Misawa; Hiroki Mori; Shinichi Hasegawa; Taketoshi Okawada; Takachika Ozawa; Shigeru Momiki; Yoshiro Nishiwaki
Journal:  Clin J Gastroenterol       Date:  2011-12-28

Review 6.  Pancreatic Cysts and Guidelines.

Authors:  James J Farrell
Journal:  Dig Dis Sci       Date:  2017-05-20       Impact factor: 3.199

7.  Implications of imaging criteria for the management and treatment of intraductal papillary mucinous neoplasms - benign versus malignant findings.

Authors:  Thula Cannon Walter; Ingo G Steffen; Lars H Stelter; Martin H Maurer; Marcus Bahra; Wladimir Faber; Fritz Klein; Hendrik Bläker; Bernd Hamm; Timm Denecke; Christian Grieser
Journal:  Eur Radiol       Date:  2014-11-30       Impact factor: 5.315

8.  Outcomes of primary surveillance for intraductal papillary mucinous neoplasm.

Authors:  Christy E Cauley; Joshua A Waters; Ryan P Dumas; Juliana E Meyer; Mohammad A Al-Haddad; John M DeWitt; Keith D Lillemoe; C Max Schmidt
Journal:  J Gastrointest Surg       Date:  2011-11-17       Impact factor: 3.452

9.  Natural history of asymptomatic pancreatic cystic neoplasms.

Authors:  Gareth Morris-Stiff; Gavin A Falk; Sricharan Chalikonda; R Matthew Walsh
Journal:  HPB (Oxford)       Date:  2012-07-23       Impact factor: 3.647

10.  Concomitant pancreatic adenocarcinoma in a patient with branch-duct intraductal papillary mucinous neoplasm.

Authors:  Joanna K Law; Christopher L Wolfgang; Matthew J Weiss; Anne Marie Lennon
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.